On the Horizon: HER3-Targeted Antibody-Drug Conjugates for Advanced Solid Tumors
Treatments for advanced non-small cell lung cancer (NSCLC) and breast cancer are rapidly advancing. Antibody-drug conjugates (ADCs) offer a novel approach to targeting HER3 as a method of delivering a cytotoxic payload that eliminates tumor cells. These interactive infographic activities provide an overview of HER3-targeted ADCs and up-to-date clinical trial data from recent conferences, as well as expert commentary from oncology clinicians.
This initiative is provided by Paradigm Medical Communications, LLC.
![Paradigm Medical Communications](https://stgfcmesa01.blob.core.windows.net/assets/images/paradigm_2023-08-15-154424_ujxh.jpg)
Series Courses
![A1113 Journal 2 Free CME 496x244 NOTEXT](https://prodcraftsa01.blob.core.windows.net/assets/products/_496x244_crop_top-center_none/A1113-Journal-2-FreeCME-496x244-NOTEXT.jpg 496w)
Updates on HER3-DXd Treatment of Metastatic Breast Cancer
CME: 0.25
View Course
![A1113 journal 3 freecme 496x244 notext](https://prodcraftsa01.blob.core.windows.net/assets/products/_496x244_crop_top-center_none/a1113_journal_3_freecme_496x244_notext.jpg 496w)
Updates on HER3-DXd Treatment of Advanced NSCLC
CME: 0.25
View Course